Meta-Analysishigh evidence
Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials.
Journal of Alzheimer's disease : JAD·July 11, 2026·PMID 42434897
Why it mattersARIA is a key safety concern limiting the clinical use of anti-amyloid therapies, yet comparative risk data have been lacking. This analysis provides head-to-head risk estimates across available agents and clarifies the strong modifying effect of APOE ε4 genotype, directly informing treatment selection and monitoring protocols.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled